Federal contract award
75A50118C00012
JANSSEN - TPOM OT AGREEMENT
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST SHARING |
| Obligations | $56.6M |
| Current contract value | $56.6M |
| Potential contract value / ceiling | $226.4M |
| Start date | Sep 21, 2018 |
| Current end date | Dec 31, 2025 |
| Potential end date | Dec 31, 2025 |
| Latest award activity | Sep 26, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 23 of 23 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 26, 2025 | P00023 | $-2.2M | JANSSEN - TPOM OT AGREEMENT |
| Aug 21, 2025 | P00022 | $0 | JANSSEN - TPOM OT AGREEMENT |
| Aug 8, 2025 | P00021 | $0 | JANSSEN - TPOM OT AGREEMENT |
| Mar 19, 2025 | P00020 | $0 | JANSSEN - TPOM OT AGREEMENT |
| Aug 29, 2024 | P00019 | $4.7M | JANSSEN - TPOM OT AGREEMENT |
| Mar 15, 2024 | P00018 | $0 | JANSSEN - TPOM OT AGREEMENT |
| Sep 26, 2023 | P00017 | $4.4M | JANSSEN - TPOM OT AGREEMENT |
| Sep 15, 2023 | P00016 | $0 | JANSSEN - TPOM OT AGREEMENT |
| Sep 1, 2023 | P00015 | $0 | JANSSEN - TPOM OT AGREEMENT |
| Jun 2, 2023 | P00014 | $10.0M | JANSSEN - TPOM OT AGREEMENT |
| Dec 12, 2022 | P00013 | $0 | JANSSEN - TPOM OT AGREEMENT |
| Aug 2, 2022 | P00012 | $2.6M | JANSSEN - TPOM OT AGREEMENT |
| Sep 17, 2021 | P00011 | $0 | JANSSEN - TPOM OT AGREEMENT |
| Sep 9, 2021 | P00010 | $2.5M | JANSSEN - TPOM OT AGREEMENT |
| Jun 21, 2021 | P00009 | $0 | JANSSEN - TPOM OT AGREEMENT |
| Mar 31, 2021 | P00008 | $444.2K | JANSSEN - TPOM OT AGREEMENT |
| Jul 30, 2020 | P00007 | $0 | I. AMENDMENT PURPOSE: BY THE PARTIES? MUTUAL AGREEMENT AND WITHIN THE EXISTING AGREEMENT?S GENERAL SCOPE, THIS AMENDMENT NO. 0007 BILATERALLY ACCOMPLISHES THE FOLLOWING: A. EXTEND THE PERIOD OF PERFORMANCE OF CLIN 0001A FROM 31 JULY 2020 TO 30 JUNE |
| Jun 10, 2020 | P00006 | $3.1M | I. AMENDMENT PURPOSE: BY THE PARTIES - MUTUAL AGREEMENT AND WITHIN THE EXISTING AGREEMENT'S GENERAL SCOPE, THIS AMENDMENT NO. 0006 BILATERALLY ACCOMPLISHES THE FOLLOWING: A. UPDATE BOTH THE TPOM AND JLABS PORTIONS OF THE STATEMENT OF WORK (AT |
| Apr 30, 2020 | P00005 | $0 | I. MODIFICATION PURPOSE: THE PURPOSE OF THIS MODIFICATION IS TO ACCOMPLISH THE FOLLOWING: A. RESTATE COST SHARING TABLE TO REFLECT THE DOWNWARD ADJUSTMENT OF $984,751 BASED ON THE JANSSEN REDUCED COST SHARE WITHIN CLIN0001A THAT WAS NOT CLEARLY ID |
| Feb 14, 2020 | P00004 | $2.2M | I. AMENDMENT PURPOSE: THE PURPOSE OF THIS MODIFICATION IS TO ACCOMPLISH THE FOLLOWING: A. EXERCISE CLIN0041, JLABS @ WASHINGTON DC, LATE STAGE SET-UP (PHASE 2) ACTIVITIES, B. IN RESPONSE TO THE CURRENT NOVEL CORONAVIRUS (?COVID-19?) OUTBREAK, A |
| Jan 31, 2020 | P00003 | $0 | I. AMENDMENT PURPOSE: THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE END DATE OF THE PERIOD OF PERFORMANCE OF CLIN 0027 FROM 31 JANUARY 2020 TO 30 APRIL 2020 AT NO ADDITIONAL COST. II. AMENDMENT CHANGES: THE PERIOD OF PERFORMANCE OF CLIN 0027 I |
| Apr 3, 2019 | P00001 | $473.1K | JANSSEN - TPOM OT AGREEMENT |
| Sep 21, 2018 | 0 | $28.3M | JANSSEN - TPOM OT AGREEMENT |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.